BC
BCAB.US Bioatla Inc
- Market cap
- USD 2.59M
- P/E
- -
- P/B
- 2.68x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BCAB.US undervalued?
Graham numberThe Graham number of Bioatla Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bioatla Inc fundamental analysis
No fundamental analysis for Bioatla Inc yet.
Bioatla Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal …
Full company profileBioatla Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bioatla Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 10.6M | 5.20M | 429K | 250K | 0.00 | 0.00 | 11.0M | 2.00M | 13.0M |
| Gross Profit | -15.7M | -20.7M | -19.5M | -58.0M | -1.20M | -1.22M | 10.1M | -41.1M | 12.8M |
| Operating Income | -28.2M | -28.3M | -30.1M | -96.4M | -108M | -130M | -73.9M | -59.3M | -18.2M |
| EBITDA | -27.2M | -27.4M | -33.5M | -94.1M | -105M | -122M | -68.9M | -59.2M | -12.4M |
| Net Income | -29.0M | -29.8M | -35.9M | -95.4M | -105M | -123M | -69.8M | -59.6M | -11.8M |
| EPS | -67 | -44 | -53 | -138 | -135 | -129 | -72 | -51 | -7.09 |
| Balance Sheet | |||||||||
| Total Assets | 16.6M | 9.34M | 245M | 254M | 226M | 120M | 52.4M | 13.8M | 9.51M |
| Total Liabilities | 45.1M | 65.3M | 35.0M | 43.6M | 45.4M | 49.0M | 38.2M | 50.0M | 45.7M |
| Shareholders' Equity | -28.5M | -56.0M | 210M | 211M | 180M | 70.7M | 14.3M | -36.2M | -36.2M |
| Cash & Short-term Investments | 10.9M | 3.70M | 239M | 245M | 216M | 111M | 49.0M | 7.12M | 1.54M |
| Total Debt | 15.0M | 18.1M | 682K | 5.37M | 3.98M | 2.46M | 836K | 6.20M | 5.86M |
| Cash Flow | |||||||||
| Operating Cash Flow | -35.3M | -9.65M | -36.3M | -62.2M | -90.4M | -104M | -71.9M | -48.2M | -11.4M |
| Capital Expenditure | 988K | 1.51M | 590K | 924K | 268K | 98.0K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -36.3M | -11.2M | -36.9M | -63.1M | -90.7M | -104M | -71.9M | -48.2M | -11.4M |
| Ratios | |||||||||
| ROE | - | - | -17.1% | -45.3% | -58.4% | -174.7% | -489.1% | - | - |
| ROA | -174.2% | -319.1% | -14.6% | -37.5% | -46.6% | -103.2% | -133.1% | -431.1% | -124.0% |
| Net Profit Margin | -272.7% | -573.0% | -8,357.3% | -38,160.8% | - | - | -634.3% | -2,980.4% | -90.6% |
| Debt to Equity | - | - | 0.00x | 0.03x | 0.02x | 0.03x | 0.06x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bioatla Inc dividends
Bioatla Inc has not paid dividends in the last 8 fiscal years.
Last stock split: 1:50 on Apr 6, 2026.
Who owns Bioatla Inc
- Insiders 6.91%
- Institutions 17.66%
- Public & others 75.44%
- Shares outstanding 1.67M
- Free float 1.39M
Top funds holding BCAB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Xtrackers MSCI World Swap ETF 1C | 148K | 0.18% | -0.63% | Dec 2025 |
| Extended Equity Market Fund E | 97.5K | 0.12% | 0.00% | Dec 2025 |
| Extended Equity Market Fund B | 97.5K | 0.12% | 0.00% | Dec 2025 |
| NT Ext Eq Mkt Idx Fd DC Lending Tier 5 | 27.5K | 0.03% | +0.70% | Mar 2026 |
| BSF Systematic US Eq Abs Ret A2 USD | 10.5K | 0.01% | 0.00% | Dec 2025 |
| Vanguard Institutional Extnd Mkt Idx Tr | 9.16K | 0.55% | 0.00% | Jul 2026 |
| Fidelity Extended Market Index | 6.13K | 0.37% | 0.00% | Jul 2026 |
| U.S. Equity Market Fund B | 6.01K | 0.01% | 0.00% | Dec 2025 |
| U.S. Equity Market Fund | 6.01K | 0.01% | 0.00% | Dec 2025 |
| Fidelity Nasdaq Composite Index | 2.94K | 0.18% | 0.00% | Jul 2026 |
| Blackrock Extended Mkt Fund CF | 1.95K | 0.12% | 0.00% | May 2026 |
| NT Ext Equity Mkt Index Fund - NL | 1.85K | 0.11% | +196.79% | Jun 2026 |
| BlackRock Extended Equity Market Fund K | 1.66K | 0.10% | -0.24% | Jun 2026 |
| Fidelity Total Market Index | 1.61K | 0.10% | 0.00% | Jul 2026 |
| Fidelity Series Total Market Index | 1.46K | 0.09% | 0.00% | Jul 2026 |
| Northern Trust Extended Eq Market Idx | 1.40K | 0.08% | +4,882.14% | Jun 2026 |
| NT Ext Equity Mkt Index Fund - Lending | 1.40K | 0.08% | -0.07% | Jun 2026 |
| NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 1.34K | 0.08% | +174.80% | Jun 2026 |
| Spartan Total Market Index Pool A1 | 677.00 | 0.04% | 0.00% | Jul 2026 |
| Extended Equity Market Fund M | 199.00 | 0.01% | +2.05% | Jun 2026 |
Top institutions holding BCAB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 1.65M | 1.98% | 0.00% | Mar 2026 |
| Acadian Asset Management LLC | 1.23M | 1.48% | 0.00% | Mar 2026 |
| Geode Capital Management, LLC | 689K | 0.83% | +37.75% | Mar 2026 |
| Deutsche Bank AG | 525K | 0.63% | 0.00% | Mar 2026 |
| Renaissance Technologies Corp | 511K | 0.61% | -27.81% | Mar 2026 |
| BlackRock Inc | 481K | 0.58% | 0.00% | Mar 2026 |
| UBS Group AG | 376K | 0.45% | +66.41% | Mar 2026 |
| Marshall Wace Asset Management Ltd | 278K | 0.33% | -68.86% | Mar 2026 |
| Vanguard Fiduciary Trust Co | 273K | 0.33% | 0.00% | Mar 2026 |
| ADAR1 Capital Management LLC | 228K | 0.27% | +24.58% | Mar 2026 |
| State Street Corp | 151K | 0.18% | 0.00% | Mar 2026 |
| Northern Trust Corp | 103K | 0.12% | 0.00% | Mar 2026 |
| SIMPLEX TRADING, LLC | 73.9K | 0.09% | -38.62% | Mar 2026 |
| Millennium Management LLC | 70.6K | 4.24% | +28.08% | Jun 2026 |
| Stonepine Capital Management Llc | 65.4K | 0.08% | 0.00% | Mar 2026 |
| XTX Topco Ltd | 56.6K | 0.07% | -6.26% | Mar 2026 |
| Morgan Stanley - Brokerage Accounts | 55.4K | 0.07% | +26.97% | Mar 2026 |
| Mccormack Advisors International | 51.5K | 0.06% | 0.00% | Mar 2026 |
| Susquehanna International Group, LLP | 39.1K | 0.05% | -52.19% | Mar 2026 |
| StoneX Group Inc | 29.5K | 0.04% | 0.00% | Mar 2026 |
Bioatla Inc company profile
- Company name
- Bioatla Inc
- Ticker
- BCAB.US
- Exchange
- USA Stocks
- Listed since
- Dec 16, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 41
- Fiscal year end
- December
- Address
- 11085 Torreyana Road, San Diego, CA, United States, 92121
- Phone
- 858 558 0708
- Website
- bioatla.com
About Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Bioatla Inc management
7- Dr. Jay M. Short Ph.D.Co-Founder, CEO & Chairman · born 1958
- Mr. Christian J. Vasquez CPACFO & Corporate Secretary · born 1976
- Ms. Susie MelodySenior Vice President of Human Resources
- Dr. Cathy Chang Ph.D.Senior Vice President of Research & Development
- Dr. Gerhard Frey Ph.D.Senior Vice President of Technology Development
- Ms. Monica SullivanSenior Vice President of Intellectual Property & Contracts
- Ms. Sheri LydickChief Commercial Officer